Methods of treating duchenne muscular dystrophy using peptide-oligonucleotide conjugates
AssigneePepgen Corporation
InventorsCaroline GODFREY, Sonia BRACEGIRDLE, Ashling HOLLAND, Smita GUNNOO
Life of this patent
Estimating the term…
Loading patent…
AssigneePepgen Corporation
InventorsCaroline GODFREY, Sonia BRACEGIRDLE, Ashling HOLLAND, Smita GUNNOO
Estimating the term…
Disclosed are methods of treating a subject having Duchenne muscular dystrophy. The method includes administration of 1 mg/kg to 60 mg/kg of a conjugate of an oligonucleotide and a peptide covalently bonded or linked via a linker to the oligonucleotide to the subject (e.g., a subject amenable to exon 51 skipping). The peptide including at least one cationic domain including at least 4 amino acid residues and at least one hydrophobic domain including at least 3 amino acid residues, provided that the peptide includes a total of 7 to 40 amino acid residues, and provided that the at least one cationic domain includes a beta-alanine residue in combination with arginine and/or histidine residues. The oligonucleotide including a total of 12 to 40 contiguous nucleobases, wherein at least 12 contiguous nucleobases are complementary to a target sequence in a human dystrophin gene.
A method of treating a subject having Duchenne muscular dystrophy, the method comprising administering 1 mg/kg to 60 mg/kg of a conjugate of an oligonucleotide and a peptide covalently bonded or linked via a linker to the oligonucleotide,
, RBRRBH (SEQ ID NO:
, RBRRBH (SEQ ID NO:
, RBRRBRRILFQYRBRBR (SEQ ID NO:
Dependencies are inferred from the claim text.